ESTRELLA IMMUNOPHARMA, INC. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/98b0b327-ad26-455d-9e3e-fdb95bc0bb48/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-13.1M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-029357 |
| FY 2024 | $-7.3M | 2023-07-01 – 2024-06-30 | evidence 0001213900-24-082374 |
| FY 2023 | $-11.1M | 2022-07-01 – 2023-06-30 | evidence 0001213900-24-082374 |
| FY 2022 | $-1.6M | 2022-01-01 – 2022-12-31 | evidence 0001575872-23-000353 |
| FY 2021 | $-249.1k | 2021-01-06 – 2021-12-31 | evidence 0001410578-22-000598 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).